Market Analysis of Veterinary Drug Feed Ingredients - VPi Down
1. Data monitoring, the veterinary drug raw material price index (VPi) on March 2 was 83.49. The domestic veterinary raw material market lacks confidence, and weak demand is transmitted, mostly showing a wait-and-see attitude.
2. In terms of the market, due to the large space for negotiation of offers of mainstream categories recently, the market transaction prices have fallen, and there is still no obvious sign of improvement in downstream demand. The trade channel shipments are still sluggish, and the industry's mentality has turned pessimistic. Secretly ship at low prices to ease risk pressure. The purchasing mentality of mid-stream and downstream users is weak, it is difficult to follow up the firm offer, and the transaction continues to negotiate and compare prices. It is expected that the actual transaction price in the market may continue to be lowered. The trade channel has high enthusiasm for shipments, but the pace of shipments is relatively slow. The wait-and-see sentiment will continue to increase, and the main sales market will still maintain the previous trend.
3. Raw materials for veterinary drugs: The market performance of raw materials for veterinary drugs continues to be poor. Over time, the market has not improved significantly, the downstream demand is not strong, and the market is mainly purchased in low quantities. Negotiated prices of mainstream factories have dropped significantly, and the competitive attitude is obvious, in order to promote market transactions, such as: florfenicol, tilmicosin, tyvalsin, etc. The trade channel maintains a low inventory, and the small and medium-sized orders are mainly purchased and sold.
4. Vitamins: The domestic vitamin market has been weak recently, and the market demand is not strong and shrinking. There are still some inventory positions in the middle and downstream markets. At the current price range of various categories, it is difficult to mobilize the willingness to purchase, and low-volume replenishment is the mainstay. Mainstream factories are willing to support prices, but affected by market expectations, the middle and lower reaches have a strong wait-and-see mood, the real orders are flat, and the profits are low. It is expected that the overall transaction volume will not increase significantly in the short term, and the market may be dominated by loose bargaining transactions, and later pay attention to factory production and delivery.
Looking for chemical products? Let suppliers reach out to you!
2026-06-28
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Market Analysis of Domestic Veterinary Drug Raw Materials in the 34th Week of 2022
-
The Veterinary Drug Industry is Facing a Period of Opportunity for Change, and Leading Animal Health Companies are Expected to Grow Rapidly
-
Analysis of China's Veterinary Drug Raw Material Market in the 32nd Week of 2022(1)
-
Analysis of the Domestic Veterinary Drug Raw Material Market in the 28th Week of 2022
-
Week 21 Partial Veterinary Drug Quotes 2
-
Analysis of The Veterinary Drug Raw Material Market in the 21st Week
-
Market Analysis of Veterinary Drug Raw Materials
-
Continue to Crack Down On The Illegal Use of Veterinary Drugs And Additives in 2022
-
Many Factors Affecting The Price Trend of Veterinary Drug Raw Materials
-
Analysis of The Domestic Veterinary Drug Raw Material Market In The Seventh Week of 2022-1
Recommend Reading
-
FDA Orders Removal of “Suicidality Warning”: Are Weight-Loss Blockbusters Finally Cleared—or Is Regulators Giving the Market a Reality Check?
-
Pharma’s Tightrope in 2026: Safety, Competition and the Future of Obesity Treatment Innovation
-
Novo Nordisk Sounds the Alarm: Growth Headwinds Loom Over Global Operations in 2026
-
Sun Pharma’s Utreglutide Shows Promising Weight Loss and Liver Fat Reduction
-
Biocon Weighs Merger of Biocon Biologics to Unlock Value
-
In October, China's BDO market showed a weak consolidation
-
Phosphate Market Prices Slightly Increase (10.27-10.31)
-
October 31st, the domestic epichlorohydrin market price remains stable
-
October Demand Weak, Phenol Market Plummets in China
-
October Methanol Market Shows Wide Fluctuations in China